A EUPATI colabora com um vasto leque de stakeholders dentro do panorama da educação do paciente e do envolvimento do paciente. Os diferentes grupos abaixo contribuem para garantir que a EUPATI continue a oferecer formação e educação de alta qualidade sobre o desenvolvimento de medicamentos aos pacientes e aos representantes dos pacientes, a título de forma a permitir um envolvimento mais sistemático e significativo dos doentes.


EUPATI Sustaining Partners

EUPATI is a public-private partnership composed by a collaborative multi-stakeholder representing patient organisations, not-for-profit, pharmaceutical industry and academic institutions. EUPATI’s strength is its community of dedicated and committed organisations and individuals who believe in its mission to support quality patient engagement through education. Click here to see the list of the Sustaining Partners in 2020 (this list is continuously updated as new partners join).


The EUPATI Patient Expert Training Course graduates form the EUPATI Alumni, which is to encompass over 200 individuals by 2021. The Alumni represents different countries and disease areas and has demonstrated expert-level knowledge and understanding of the medicines R&D process. The Alumni is active in e.g. patient organisations and providing advice to industry, regulator and HTA partners. The Alumni is also engaged in producing and reviewing new course and toolbox content for EUPATI.

Friends of EUPATI

An important number of individuals have contributed to EUPATI in different capacities since its launch. These individuals are highly valued by EUPATI as they have committed their time and expertise for the benefit of our shared vision. The ‘Friends of EUPATI’ group includes e.g.:

– Former Consortium Partners (incl. former Steering Group Members)

– Former Ethics Panel Members

– Former Secretariat staff

– Non-Consortium Contributors

– Advisors

More information of activities of this group is to follow.

Collaboration with other initiatives

EUPATI maintains several important partnerships with external actors in the patient engagement field. Some of these are listed below. In addition, EUPATI has close partnerships with national health councils and regulatory agencies (including the European Medicines Agency, EMA). EU-associated organisations, providing the opportunity for funding, such as IMI and EIT, are additional key partners for EUPATI.

European Patients’ Forum

EPF has played a leading role in EUPATI since its inception and has hosted the consortium as a programme since 2017. Their leadership and commitment to EUPATI to date, its transition and support for the Foundation is a fundamental critical success factor for the future model. The EUPATI Foundation will continue to maintain a close relationship with EPF, as reflected in the governance structure.

Patient Focused Medicines Development (PFMD)

Under the EUPATI-PFMD partnership on patient engagement, PFMD coordinates and leads on knowledge generation, and EUPATI coordinates and leads on the development and delivery of education and training, which in certain parts is performed by PFMD.


EUPATI collaborates closely with the IMI-project PARADIGM, on patient engagement resources and dissemination of the project outcomes.

The Organisation for Professionals in Regulatory Affairs (TOPRA)

The EUPATI-TOPRA collaboration focuses on communication and outreach channels. It also involves development of lay language educational materials about regulation of medicines.


Patvocates add tailored education to standardised EUPATI modules, targeting the same market. Patvocates is a social enterprise investing a percentage of its turnover in patient engagement initiatives such as the EUPATI Foundation.